Fate Therapeutics Inc Total Liabilities
Fate Therapeutics Inc total liabilities. Based on the latest financial reports, Fate Therapeutics Inc (FATE) has total liabilities worth $109.61 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Fate Therapeutics Inc's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Fate Therapeutics Inc (2011–2024)
Total liabilities of Fate Therapeutics Inc from 2011 to 2024. This chart illustrates how Fate Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore FATE strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Fate Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Fate Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Varia US Properties Ltd
SW:VARN
|
Switzerland | CHF656.47 Million |
|
Ibraco Bhd
KLSE:5084
|
Malaysia | RM915.91 Million |
|
Chialin Precision Industrial Co Ltd
TWO:3310
|
Taiwan | NT$4.18 Billion |
|
Bank Artha Graha Internasional
JK:INPC
|
Indonesia | Rp28.83 Trillion |
|
Otello Corporation ASA
OL:OTEC
|
Norway | Nkr1.70 Million |
|
Heungkuk F&M I
KO:000540
|
Korea | ₩12.24 Trillion |
|
Cloud Technologies S.A
WAR:CLD
|
Poland | zł11.32 Million |
|
ZHOU HEI YA HLDG -000001
F:ZHY
|
Germany | €861.45 Million |
Liability Composition Analysis (2011–2024)
This chart breaks down Fate Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see FATE current and non-current assets.
Liquidity & Leverage Metrics
Fate Therapeutics Inc Total Liabilities Ratios Explained
Fate Therapeutics Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.47 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Fate Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Fate Therapeutics Inc (2011–2024)
The table below shows the annual total liabilities of Fate Therapeutics Inc from 2011 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $121.97 Million | -11.49% |
| 2023-12-31 | $137.80 Million | -37.82% |
| 2022-12-31 | $221.62 Million | -8.65% |
| 2021-12-31 | $242.62 Million | +1.93% |
| 2020-12-31 | $238.01 Million | +313.80% |
| 2019-12-31 | $57.52 Million | +9.43% |
| 2018-12-31 | $52.56 Million | +87.04% |
| 2017-12-31 | $28.10 Million | +28.36% |
| 2016-12-31 | $21.89 Million | -26.82% |
| 2015-12-31 | $29.92 Million | +30.86% |
| 2014-12-31 | $22.86 Million | +382.87% |
| 2013-12-31 | $4.74 Million | -92.59% |
| 2012-12-31 | $63.90 Million | +9.17% |
| 2011-12-31 | $58.53 Million | -- |
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders in the United States and internationally. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma; FT836 whiuch is in preclinical stage for multiple tumor types; and FT522, to treat… Read more